Nemaura Medical (NASDAQ:NMRD) vs. Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Survey

Nemaura Medical (NASDAQ:NMRD) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Nemaura Medical and Vivos Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemaura Medical	0	0	0	0	N/A
Vivos Therapeutics	0	0	1	0	3.00

Vivos Therapeutics has a consensus price target of $6.60, indicating a potential upside of 122.97%. Given Vivos Therapeutics’ higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Nemaura Medical.

Profitability

This table compares Nemaura Medical and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemaura Medical	N/A	N/A	-142.69%
Vivos Therapeutics	-85.90%	-652.32%	-98.95%

Valuation and Earnings

This table compares Nemaura Medical and Vivos Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemaura Medical	$3,017.00	414.62	-$14.14 million	($0.39)	-0.08
Vivos Therapeutics	$14.02 million	0.68	-$13.58 million	($10.93)	-0.27

Vivos Therapeutics has higher revenue and earnings than Nemaura Medical. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Nemaura Medical has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.74, indicating that its share price is 674% more volatile than the S&P 500.

Institutional & Insider Ownership

4.4% of Nemaura Medical shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 40.4% of Nemaura Medical shares are held by insiders. Comparatively, 9.6% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vivos Therapeutics beats Nemaura Medical on 7 of the 13 factors compared between the two stocks.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.